1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,350 | 7,600 | 13.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| Fr | WUXI XDC (02268): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 12, 2025 | 1 | HKEx | ||
| 01.12. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 25.11. | WUXI XDC (02268): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, DECEMBER 12, 2025 | 1 | HKEx | ||
| 25.11. | WUXI XDC (02268): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 25.11. | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAP FOR THE EXISTING ANTIBODIES MASTER SERVICES AGREEMENT (2) RENEWAL OF THE ... | 2 | HKEx | ||
| 25.11. | WUXI XDC (02268): CLOSURE OF REGISTER OF MEMBERS | - | HKEx | ||
| 25.11. | WUXI XDC (02268): SUPPLEMENTAL ANNOUNCEMENT CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAPS FOR RELEVANT CCT AGREEMENTS; (2) RENEWAL OF ... | - | HKEx | ||
| 21.11. | UBS stuft WuXi XDC mit "Buy" ein - starkes Wachstum im Biokonjugat-Markt erwartet | - | Investing.com Deutsch | ||
| 23.10. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 23.10. | WUXI XDC (02268): COMPLETION OF CONNECTED TRANSACTION INVOLVING SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE | 3 | HKEx | ||
| 09.10. | WUXI XDC (02268): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 9, 2025 | - | HKEx | ||
| 26.09. | WUXI XDC (02268): INTERIM REPORT 2025 | 2 | HKEx | ||
| 23.09. | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAPS FOR RELEVANT CCT AGREEMENTS; (2) RENEWAL OF EXISTING CCT AGREEMENTS; AND ... | 3 | HKEx | ||
| 22.09. | WUXI XDC (02268): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, OCTOBER 9, 2025 | 1 | HKEx | ||
| 22.09. | WUXI XDC (02268): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 22.09. | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 19.09. | WUXI XDC (02268): CLOSURE OF REGISTER OF MEMBERS | 3 | HKEx | ||
| 10.09. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 03.09. | BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount | 5 | Bamboo Works | ||
| 03.09. | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE | 1 | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,06 | -0,56 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,110 | +5,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,08 | +0,72 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| HARMONY BIOSCIENCES | 40,510 | +2,32 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,83 | +0,32 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| LENZ THERAPEUTICS | 18,140 | -25,96 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,020 | -1,53 % | Amit Munshi joins Arcutis board as founder Chaudhuri retires | ||
| ARCELLX | 71,86 | -1,14 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| MINERALYS THERAPEUTICS | 36,890 | +2,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 33,040 | +4,62 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| KYMERA THERAPEUTICS | 89,67 | +2,12 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 41,590 | +1,41 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,330 | -5,46 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| IMMUNOVANT | 26,430 | +6,53 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,29 % bei einem Aktienkurs von 7,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.